Mauricio Leal
Overview
Explore the profile of Mauricio Leal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hooper A, Marquette K, Chang C, Golas J, Jain S, Lam M, et al.
Mol Cancer Ther
. 2022 Jul;
21(9):1462-1472.
PMID: 35793468
Extra domain B splice variant of fibronectin (EDB+FN) is an extracellular matrix protein (ECM) deposited by tumor-associated fibroblasts, and is associated with tumor growth, angiogenesis, and invasion. We hypothesized that...
2.
Gupta P, Jiang Z, Yang B, Manzuk L, Rosfjord E, Yao J, et al.
MAbs
. 2021 Aug;
13(1):1958662.
PMID: 34347577
IL13Rα2 is a cell surface tumor antigen that is overexpressed in multiple tumor types. Here, we studied biodistribution and targeting potential of an anti-IL13Rα2 antibody (Ab) and anti-tumor activity of...
3.
Han Y, Kahler J, Piche-Nicholas N, Hu W, Thibault S, Jiang F, et al.
Clin Cancer Res
. 2020 Nov;
27(2):622-631.
PMID: 33148666
Purpose: Mortality due to acute myeloid leukemia (AML) remains high, and the management of relapsed or refractory AML continues to be therapeutically challenging. The reapproval of Mylotarg, an anti-CD33-calicheamicin antibody-drug...
4.
Gupta P, Wentland J, Leal M, Ma D, Roach R, Esparza A, et al.
Oncotarget
. 2017 Sep;
8(34):57231-57245.
PMID: 28915667
Non-invasive imaging using radiolabels is a common technique used to study the biodistribution of biologics. Due to the limited shelf-life of radiolabels and the requirements of specialized labs, non-invasive optical...
5.
Rago B, Clark T, King L, Zhang J, Tumey L, Li F, et al.
Bioanalysis
. 2016 Sep;
8(21):2205-2217.
PMID: 27682846
Aim: Complex nature of bioconjugates require multiple bioanalytical approaches to support PK and absorption, distribution, metabolism and excretion characterization. For antibody-drug conjugate (ADC) bioanalysis both LC-MS and ligand-binding assays (LBAs)...
6.
Giddabasappa A, Gupta V, Norberg R, Gupta P, Spilker M, Wentland J, et al.
Mol Cancer Ther
. 2016 Jul;
15(10):2530-2540.
PMID: 27466353
Understanding a drug's whole-body biodistribution and tumor targeting can provide important information regarding efficacy, safety, and dosing parameters. Current methods to evaluate biodistribution include in vivo imaging technologies like positron...
7.
Leal M, Wentland J, Han X, Zhang Y, Rago B, Duriga N, et al.
Bioconjug Chem
. 2015 Jul;
26(11):2223-32.
PMID: 26180901
The pharmacokinetics of an antibody (huA1)-drug (auristatin microtubule disrupting MMAF) conjugate, targeting 5T4-expressing cells, were characterized during the discovery and development phases in female nu/nu mice and cynomolgus monkeys after...
8.
Visintin A, Knowlton K, Tyminski E, Lin C, Zheng X, Marquette K, et al.
Mol Cancer Ther
. 2015 Jun;
14(8):1868-76.
PMID: 26089370
Antibody-drug conjugates (ADC) represent a promising therapeutic modality for managing cancer. Here, we report a novel humanized ADC that targets the tetraspanin-like protein TM4SF1. TM4SF1 is highly expressed on the...
9.
Hu G, Leal M, Lin Q, Affolter T, Sapra P, Bates B, et al.
Mol Pharm
. 2014 Nov;
12(6):1730-7.
PMID: 25423493
The use of predictive preclinical models in drug discovery is critical for compound selection, optimization, preclinical to clinical translation, and strategic decision-making. Trophoblast glycoprotein (TPBG), also known as 5T4, is...
10.
Leal M, Sapra P, Hurvitz S, Senter P, Wahl A, Schutten M, et al.
Ann N Y Acad Sci
. 2014 Aug;
1321:41-54.
PMID: 25123209
Antibody-drug conjugates (ADCs) offer promise as a therapeutic modality that can potentially reduce the toxicities and poor therapeutic indices caused by the lack of specificity of conventional anticancer therapies. ADCs...